Effect of blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study
Open Access
- 10 May 2011
- Vol. 342 (may10 2), d2549
- https://doi.org/10.1136/bmj.d2549
Abstract
Objective To examine the effect of β blockers in the management of chronic obstructive pulmonary disease (COPD), assessing their effect on mortality, hospital admissions, and exacerbations of COPD when added to established treatment for COPD. Design Retrospective cohort study using a disease specific database of COPD patients (TARDIS) linked to the Scottish morbidity records of acute hospital admissions, the Tayside community pharmacy prescription records, and the General Register Office for Scotland death registry. Setting Tayside, Scotland (2001–2010) Population 5977 patients aged >50 years with a diagnosis of COPD. Main outcome measures Hazard ratios for all cause mortality, emergency oral corticosteroid use, and respiratory related hospital admissions calculated through Cox proportional hazard regression after correction for influential covariates. Results Mean follow-up was 4.35 years, mean age at diagnosis was 69.1 years, and 88% of β blockers used were cardioselective. There was a 22% overall reduction in all cause mortality with β blocker use. Furthermore, there were additive benefits of β blockers on all cause mortality at all treatment steps for COPD. Compared with controls (given only inhaled therapy with either short acting β agonists or short acting antimuscarinics), the adjusted hazard ratio for all cause mortality was 0.28 (95% CI 0.21 to 0.39) for treatment with inhaled corticosteroid, long acting β agonist, and long acting antimuscarinic plus β blocker versus 0.43 (0.38 to 0.48) without β blocker. There were similar trends showing additive benefits of β blockers in reducing oral corticosteroid use and hospital admissions due to respiratory disease. β blockers had no deleterious impact on lung function at all treatment steps when given in conjunction with either a long acting β agonist or antimuscarinic agent Conclusions β blockers may reduce mortality and COPD exacerbations when added to established inhaled stepwise therapy for COPD, independently of overt cardiovascular disease and cardiac drugs, and without adverse effects on pulmonary function.This publication has 29 references indexed in Scilit:
- Characterisation of COPD heterogeneity in the ECLIPSE cohortRespiratory Research, 2010
- A Postmortem Analysis of Major Causes of Early Death in Patients Hospitalized With COPD ExacerbationSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2009
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Statin use is associated with reduced mortality in COPDEuropean Respiratory Journal, 2006
- Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary DiseaseJournal of the American College of Cardiology, 2006
- Cardioselective beta-blockers for chronic obstructive pulmonary diseaseEmergencias, 2005
- Detrimental Effects of β-Blockers in COPDSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2005
- Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control groupStatistics in Medicine, 1998
- Effect of Beta-Blockade on Mortality among High-Risk and Low-Risk Patients after Myocardial InfarctionThe New England Journal of Medicine, 1998
- Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects.British Journal of Clinical Pharmacology, 1992